RedHill Biopharma Announces Peer-Reviewed Publication Demonstrating Restorative Potential of ABC294640 (YELIVA(TM)) in …
13:04 GMT
The publication in the peer-reviewed journal Molecular Cancer cells Research information encouraging pre-clinical results suggesting ABC294640 dramatically inhibits prostate cancer cells lump development RedHill filed a hallmark application with the united state Patent and also Trademark Workplace for the new brand YELIVA ™ for ABC294640 YELIVA ™ (ABC294640) is a proprietary, first-in-class, orally-administered … (proceed reviewing)
No comments:
Post a Comment